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 Abstract  
Hyaluronic acid (HA) is a key component of the extracellular matrix known for absorbing 
water, swelling, and altering solid stress of tumors. HA’s anionic behavior may provide 
important biochemical effects toward tumor progression as well. Tumors obtain nutrients 
by relying on signaling molecules such as CXCL12 to recruit blood vessels and promote 
vessel leakage.  Recent work suggests that additional positively-charged residues on 
CXCL12’s β and γ isoforms cause different biochemical functionality compared to the 
well-studied α isoform. These studies aimed to determine whether the presence of HA in 
a tumor’s microenvironment could alter the relative response strength of CXCL12’s 
various isoforms on blood vessel sprouting and apparent vascular permeability. The 
vessel microenvironment was modeled using a 3-channel microfluidic device with Human 
Umbilical Vein Endothelial Cells (HUVECs) in the outer channels forming monolayers 
against a 3D collagen or collagen/HA matrix in the center channel. HUVECs were cultured 
with media containing recombinant CXCL12 (α, β or γ).  Results show that total HUVEC 
sprouting area follows an α>β>γ trend in isoform-treated HUVECs within a collagen 
matrix, matching the binding affinity order of CXCL12 to endothelial CXCR4 receptors. 
The presence of HA decreased overall sprouting response but shifted pro-angiogenic 
potency towards CXCL12’s γ isoform. Vascular permeability studies also showed an α> 
β>γ trend for HUVECs in collagen. With HA added, control and α-treated HUVECs 
became less permeable while γ-treated HUVECs became more permeable.  Overall 
results suggest that an HA-infused collagen matrix facilitates γ isoform binding, leading 
to a stronger isoform-specific vessel response. Knowing how HA impacts CXCL12 isoform 
potency on vessels will help in the future design of CXCL12-targeted cancer therapies.  
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1.1 Literature Overview 
1.1.1 Tumor microenvironment and reliance on blood vessels 
In the early 1970s, a medical scientist by the name of Judah Folkman noticed that tumors 
struggled to grow to a meaningful size when in the absence of an external blood 
supply[1],[2]. This observation prompted his idea to combat cancer progression by 
preventing new blood vessel formation. Folkman’s insight pushed for a new movement in 
cancer research focusing on how tumors interact with vessels and other factors in the 
microenvironment around them.   
 
The tumor microenvironment (TME), depicted in Figure 1.1[3], refers to all the other cells 
and molecules surrounding the tumor at the micro scale, most notably the extracellular 
matrix (ECM) and blood vessels. The ECM is composed mainly of collagen, a fibrous 
protein secreted by stromal cells that serves as structural support for neighboring cells. 
Other components include the stromal cells themselves as well as various 
glycosaminoglycans such as hyaluronic acid. Blood microvessels at this scale are 
essentially single-layer tubes of endothelial cells.  In tumors, these vessels become highly 




Figure 1.1: Tumor Microenvironment[3]  
The tumor microenvironment includes three main components: the tumor, the blood/lymphatic vessels, 
and the extracellular matrix (ECM) or tissue stroma. 
One way tumor cells manipulate blood vessels is by recruiting them in an effort to obtain 
enough nutrients to rapidly grow and proliferate[5]. In a process called angiogenesis, new 
sprouts can emerge from pre-existing blood vessels.  Angiogenesis is upregulated in the 
TME, resulting in highly irregular blood vessel networks that infiltrate the entire tumor, 
shown in Figure 1.2[6].  
 
Figure 1.2: Angiogenic Vessel Recruitment in Solid Tumors[6] 
 Tumors are capable of inducing angiogenic behavior in vessels in order to receive sufficient nutrients. 
Vessel leakiness or permeability tends to be significantly increased in the TME as well. 
VE-cadherin, a type of cell adhesion molecule that holds endothelial cells together at gap 
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junctions, becomes degraded in the presence of some tumors[4].  Reorganization of VE-
cadherin can result in the widening of these junctions, and more fluid is allowed to leak 
or permeate through the vessel wall. Widened junctions between adjacent endothelial 
cells facilitate the invasion of primary tumor cells into the vasculature[7]. Once in the 
bloodstream, tumor cells can extravasate elsewhere to form secondary tumors. That 
process, known as metastasis, is shown in Figure 1.3[8]. Metastatic cancer often proves 
much deadlier than cancers involving just the primary tumor[9], so preventing invasion 
through leaky vessels becomes an important issue to address. 
 
Figure 1.3: Primary Tumor Metastasis to Secondary Site[8] 
 Tumor cells can invade blood vessels at leaky junctions, travel through the blood stream, and exit 
elsewhere in the body to form secondary tumors. 
It has been well studied that vessel angiogenesis and vascular permeability are mediated 
by growth factors and other signaling molecules expressed in the TME[4],[5]. Vascular 
endothelial growth factor (VEGF), for example, is a signaling protein that cells secrete in 
response to hypoxia to induce blood vessel growth and enhance oxygen supply. 
Endothelial cells express the VEGF-activated receptor VEGFR. Most tumor cells have 
been shown to overexpress growth factors such as VEGF, allowing them to promote 
angiogenesis. Chemokines are other signaling molecules that can induce a chemotactic 
migratory response (movement in the direction of a chemical gradient) in cells that 
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express the appropriate receptors. Chemokine (C-X-C motif) ligand 12 (CXCL12), for 
example, can bind to its receptor CXCR4 on endothelial cells to induce cell motility[10].  
 
1.1.2 CXCL12 signaling and binding affinities 
Chemokine (C-X-C motif) Ligand 12 (CXCL12) is a type of chemotactic signaling protein 
that promotes gradient-directed migratory behavior in cells that contain its receptor 
CXCR4[10].  Both cancer cells and endothelial cells have been found to express this 
receptor, and CXCL12 is known to be heavily expressed in the TME. Given its migratory 
influence, CXCL12 is often studied in the context of tumor cell metastasis. Focusing 
instead on endothelial cells, CXCL12 treatment has been known to contribute to the 
formation of new vessel sprouts and disruption of vessel integrity[10]. Provided CXCL12’s 
further impact on vessel behavior, it becomes a multi-faceted target for stopping tumor 
progression. 
 
Like many signaling proteins, CXCL12 exists as a number of different isoforms[10], which 
are similar proteins with slight differences in amino acid sequences. Three main isoforms 
(α, β and γ) are expressed by rats, mice, and humans, and these isoforms are known to 
be elevated in breast tumors[10]. Humans also express three other isoforms in lesser 
quantities (δ, ε, and φ) that are not as well-studied. CXCL12-α has been shown to activate 
CXCR4 receptors with a significantly greater potency than the β and γ isoforms (binding 
affinity follows an α>β>γ trend), leading several studies to focus only on the α isoform. 
However, recent work suggests that the β and γ isoforms can elicit meaningful responses 
in cancer and endothelial cells depending on the cancer type and composition of the 
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TME[10]. Paramita et al. demonstrate that CXCL12-β and γ increase angiogenesis in 
HUVECs (endothelial cells) compared to CXCL12-α, while CXCL12-γ also promotes 
metastasis in CXCR4-containing breast cancer cells[10].  
 
An important difference between the CXCL12-α, β, and γ isoforms is that additional 
positively-charged amino acid residues are present on the carboxy-terminal side of the β 
and γ isoforms[10].   Therefore, a more negatively-charged matrix may provide a binding 
surface for positively-charged CXCL12 molecules to be sequestered within the matrix, 
augmenting the potencies of the matrix-bound isoforms.  It is known that the binding 
affinity strengths of CXCL12 isoforms to negatively-charged ECM follows the trend of 
γ>β>α.  Amplifying this trend could cause a shift in CXCL12 isoform potency toward the 
γ direction and could be a factor for why the CXCL12-β and γ isoforms become more 
active in certain tissues. As a result, an interesting question to explore is how the ECM 
binding affinities of CXCL12 isoforms impact CXCR4-mediated responses.   
 
1.1.3 Hyaluronic acid in the extracellular matrix 
Hyaluronic acid (HA) is a highly negatively-charged glycosaminoglycan and major 
component of the ECM[11]. HA’s negative charge causes it to readily absorb water and 
swell, often leading to stiffer matrices in tissues. Apart from its structural role, HA plays a 
role in mediating cell migration and proliferation as well as maintaining blood vessel 
integrity[12]. The ECM tends to overexpress HA production in several cancer types (i.e. 
pancreatic and breast), and increased HA concentration around tumors is a marker for 
worse survival in patients[13]. One reason for this is that HA contributes to increased solid 
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stress in the tumor microenvironment[14], impairing vessel function leading to leakier 
vessels. Increased solid stress by HA compresses blood vessels as well, blocking drug 
perfusion[15]. HA in the TME is depicted in Figure 1.4[16] below. 
 
Figure 1.4: Hyaluronic Acid’s Role in the Tumor Microenvironment[16] 
 Hyaluronic Acid upregulation in tumors has been shown to disrupt vessel integrity, increase 
transvascular permeability through solid stress, and block drug perfusion through vessels. 
Hyaluronic Acid (HA) exists in the body at varying sizes and molecular weights.  Intact, 
high molecular weight HA (HMW-HA) is attributed with maintaining vessel integrity 
through interactions with CD44 receptors on endothelial cells[17]. HMW-HA can get 
degraded by hyaluronidase and other reactive oxygen species into lower molecular 
weight HA (LMW-HA). Interestingly, studies show that LMW-HA leads to degraded vessel 
integrity while HMW-HA strengthens vessel integrity[18]. 
 
The biomechanical properties of HA play a large role in governing how blood vessels 
behave in the TME.  HA’s negative charge distribution could affect signaling-induced 
vessel response as well by biochemically altering signaling protein binding behavior. 
However, few studies have looked at how HA’s negative charge could influence 
chemokine interaction with blood vessels. The chemokine CXCL12, with its three major 




isoforms having different electrochemical properties, serves as a good target for studying 
how HA’s negative charge can influence blood vessel response to signaling proteins. 
 
1.2 Objectives and research significance 
The objective of this research is to investigate whether hyaluronic acid’s biochemical 
properties could affect signaling protein stimulation of blood vessels in the tumor 
microenvironment. Most research involving hyaluronic acid (HA) and its influence on 
blood vessels focuses on the additional mechanical forces expressed when HA-rich 
matrices swell[18]. HA has a strong inherent negative charge, and some studies have 
suggested that HA can affect cell signaling[19]. These notions suggest that HA can alter 
the potency of signaling proteins such as CXCL12 in the extracellular matrix (ECM). 
CXCL12’s existence as multiple isoforms with different charge distributions makes it an 
ideal molecule to study the influence of HA’s biochemical properties on chemokine-
mediated vessel behavior.  
 
Vessel behavior will be analyzed by designing microfluidic devices to study angiogenic 
sprouting and vascular permeability in response to chemotactic CXCL12 isoforms. Both 
vessel properties will first be studied against a collagen-only matrix to study how each 
CXCL12 isoform affects vessels in the absence of HA. Experiments will be repeated with 
the addition of HA to the matrix, and vessel behavior will be compared to that of collagen-
only samples. It is hypothesized that the addition of HA will reverse the CXCL12 isoform 
potency on vessel behavior due to its dense negative charge. CXCL12 isoform rank order 
binding affinity to endothelial CXCR4 receptors (α>β>γ) is opposite the affinity for binding 
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to the ECM (γ>β>α). The addition of negatively-charged HA to the matrix may increase 
the instance of matrix-bound CXCL12, shifting vessel signaling response potency to 
better resemble the matrix binding affinity of CXCL12. A schematic of the hypothesized 
results is shown in Figure 1.5. The addition of HA may bind more positively-charged 
CXCL12-β and γ isoforms to the ECM, allowing them to induce a migratory vessel 
response more potently than the normally prominent CXCL12-α isoform. 
 
Figure 1.5: Hypothesized Effect of HA on Endothelial Cell Activation 
 (A) With collagen-only matrices, CXCL12-α has been shown to have the greatest affinity for activating 
endothelial CXCR4 receptors to induce movement. (B) Adding negatively-charged HA to the matrix may 
increase matrix-bound CXCL12, especially for more positively-charged β and γ isoforms, which would 
result in intensified signal activation. 
This research will provide insight as to whether or not the presence of HA in the tumor 
microenvironment can biochemically affect vessel behavior in addition to its known 
mechanical effects.  Understanding how HA composition affects CXCL12 isoform-specific 
activation of endothelial cells will contribute to the design of cancer therapies targeting 
CXCL12-CXCR4 signaling in the TME. An increase in CXCL12-β or γ activation of 
endothelial response with HA present would support recent research suggesting that 
those two isoforms are just as significant as CXCL12-α in some tissues. The composition 
of the TME is very heterogeneous and varies between tumor to tumor, and the importance 




2.1 Cell culture 
Human umbilical vein endothelial cells (HUVECs) (Lonza) were cultured with endothelial 
growth medium EGM-2. Cells were passaged every 4 to 5 days. All experiments were run 
with HUVECs at passage 6 to 12.  
 
2.2 Microfluidic device design and fabrication 
A microfluidic system was designed to mimic the vessel microenvironment in vitro. 
Devices were fabricated with polydimethylsiloxane (PDMS) based on a well-documented 
technique utilizing photolithography and soft lithography[20]. The fabrication process is 
outlined in Figure 2.1[21]. 
 
Figure 2.1: Microfluidic Device Fabrication 
 (a-c) Photolithography: UV light is shown through a transparent mask onto a silicon wafer, creating a 
raised surface in the shape of the designed device. (d-f) Soft lithography: PDMS is poured over the silicon 
mold, cured, and detached to form a device with microchannels.  
For this particular study, a previously designed 3-channel device was used in which a 
collagen matrix could fill the center channel while endothelial cells (HUVECs) lined the 
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two outer channels. Six apertures were present on either side of the central channel at 
which HUVECs would form monolayers against the matrix. A schematic of the design is 
shown in Figure 2.2. 
 
Figure 2.2: Three-channel Device Schematic 
(A) AutoCAD drawing of the microfluidic device. HUVECs were seeded in the outer channels against a 
collagen or collagen/HA matrix formed in the center channel. (B) Microscope image of yellow boxed-in 
region of the device (Scale bar 100 µm). Seeded HUVECs have formed monolayers against the collagen 
matrix at each of the apertures.  
 
2.3 Assay preparation 
The 3-channel system was used to analyze the potency of isolated human recombinant 
CXCL12 isoforms (α, β, or γ) on sprouting angiogenesis and apparent vascular 
permeability into a collagen or collagen/HA matrix. PDMS devices were plasma oxidized, 
adhered to glass slides, and placed in an oven (65˚C) for at least 24 hours to ensure 
suitable attachment.  Type 1 rat-tail collagen (3 mg/mL, Corning) with or without HMW 
HA (1 mg/mL, Sigma) was injected into the central channel and allowed to polymerize at 
37 ˚C in an incubator for 12 hours. A 6 mg/mL collagen gel was used instead for the 
apparent vascular permeability assay to prevent sprouting into the matrix. Outer channels 






were lined with the adherent ECM protein fibronectin (100 μg/mL, Sigma) before filling 
them with a 7.0 million cells/mL HUVEC solution. The apparent vascular permeability 
assay only required one of the outer channels to be loaded with cells. Devices were 
incubated for 12 hours with EGM2 media to allow proper cell attachment and monolayer 
formation against the collagen matrix at each of the apertures. Cells within the device 
were then cultured with EGM2 media conditioned with specific CXCL12 isoforms (α, β, or 
γ, 100 ng/mL, Peprotech). Fresh media was administered every 24 hours. 
 
2.4 Sprouting angiogenesis assay 
For the sprouting angiogenesis assay, HUVECs were cultured in vitro for an additional 3 
days after treatment with conditioned media (CXCL12-α, β, or γ, 100 ng/mL). Initial 
treatment was considered to be day 0. The HUVECs would typically sprout into the 
collagen matrix, and images were taken each day to track how much the sprouting area 
increased over time. Sprout area could be traced using ImageJ software. A ‘Sprouting 
Ratio’ percentage was calculated for each day (N = 1, 2, 3) by taking the total area 
difference since day 0 and dividing that value by a reference area of 80,000 pixels, as 
shown in Equation 2.1. The procedure for analyzing sprouting area is shown in Figure 
2.3. 
 Sprouting Ratio (%) =
𝐴𝑟𝑒𝑎 𝐷𝑎𝑦 𝑁−𝐴𝑟𝑒𝑎 𝐷𝑎𝑦 0 
𝑅𝑒𝑓.  𝐴𝑟𝑒𝑎




Figure 2.3: Analyzing HUVEC Sprouting Area in Sprouting Angiogenesis Assay 
(A) HUVECs sprouting into collagen matrix. (B) Zoomed-in image of yellow box region showing area 
tracing of HUVEC sprouts (Scale bars 100 µm). 
 
2.5 Apparent vascular permeability assay 
HUVECs were cultured for 2 days in vitro with conditioned media (CXCL12-α, β, or γ, 100 
ng/mL). 6 mg/mL collagen replaced the 3 mg/mL collagen for the apparent vascular 
permeability assay to reduce spontaneous sprouting occurrence. To test permeability, a 
red fluorescent conjugated dye (70 kDa Texas Red-labeled Dextran, 2.0 μL, 0.05 mM) 
was passively pumped into the HUVEC channel and allowed to diffuse across the 
endothelial monolayer into the collagen matrix. Pumping was performed by holding a 
droplet of dye above one of the HUVEC channel ports until the droplet made contact with 
the fluid in the channel. The surface energy in the droplet propelled the dye through. It 
was assumed that there was no pressure gradient within the microfluidic channel, 
meaning only diffusion and not convection would affect mass transfer of the dye. If 
sprouting occurred at one of the apertures, that assumption would not hold (fluid would 








A time-lapse epifluorescent microscope was used to track the intensity of the Texas Red 
dye as it diffused transvascularly into the collagen matrix, shown in Figure 2.4. ImageJ 
(NIH) software was used to identify the source intensity at each aperture and track the 
intensity change over time within specified regions. Knowing those values, an apparent 
vascular permeability value (𝑃𝐴𝑝𝑝) was calculated for the system using Equation 2.2
[22]. 
∆𝐼 represents source intensity, 𝑑𝐼/𝑑𝑡 represents a slope value for intensity change over 
time, and 𝑉𝑣/𝑆𝑣 is a volume to surface area ratio of the device’s dye-loading channel.   
 
Figure 2.4: Dye Permeating Vessels in Apparent Vascular Permeability Assay 
 Texas Red-labeled dextran diffuses across HUVEC monolayer into collagen channel over two minute 
time scale (Scale bars 100 µm). Source intensity was taken for each aperture just above the vessel 
monolayer. Intensity within the yellow boxed-in region was analyzed over time using ImageJ to determine 
a 𝑑𝐼/𝑑𝑡 value. 
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3.1 Quantifying vessel sprouting 
HUVECs were cultured for 3 days after initial treatment with isolated CXCL12 isoforms 
and observed for sprouting behavior at each aperture. Representative day 3 images for 
the collagen-only experiments are shown in Figure 3.1.   
 
Figure 3.1: Day 3 Images of HUVECs Sprouting into Collagen-only Matrix 
 HUVECs treated with CXCL12 (α, β, or γ, 100 ng/ml) show α>β>γ trend in sprouting response. CXCL12-
α exhibits the most spread-out sprouting behavior. PDMS is outline in purple. Scale bars 100 µm. 
CXCL12-α treated HUVECs appeared to elicit the strongest response in terms of 
sprouting area.  The overall sprouting response to CXCL12 seemed to follow an α>β>γ 
trend, following the reported binding affinity rank order of those isoforms to its cell receptor 
CXCR4[10]. The CXCL12-α treated HUVECs also exhibited the largest number of 
individual, highly motile cells that spread away from the initial cell monolayer.  Normally, 
a vessel sprout observed in this type of assay would consist of one to a few cells that 
form a single branch-like structure, similar to what’s seen in the CXCL12-γ treated 
HUVECs in Figure 3.1. The CXCL12-α treated cells did not show typical sprouting 
behavior but instead spread out in a fan-like manner as they moved into the collagen 
matrix. That unusual vessel behavior was partially seen in CXCL12-β treated HUVECs 






this study, any cells that moved away from the cell monolayer into the collagen matrix at 
a particular aperture were considered towards that aperture’s sprouting area.  
 
To adjust for how some sprouting could occur in the period before initial treatment, a 
sprouting ratio term was calculated that negated any sprouting present at day 0 
(described in 2.4).  Sprouting ratio at each aperture was determined each day for 3 days 
after treatment with CXCL12-conditioned media and averaged for each device. Average 
sprouting ratio by device is reported in Figure 3.2 (N = 4 devices each). 
 
Figure 3.2: Sprouting Ratio of HUVECs into Collagen Matrix over 3-Day Period 
 CXCL12-α treated HUVECs show the greatest increase in sprouting response. A significant difference 
was observed between CXCL12-α and γ treated HUVECs. Error bars expressed as SEM. Statistical 
analysis performed using one-way analysis of variance. N=4. *, P value < 0.05. 
In assessing the results, the expected α>β>γ sprouting trend of CXCL12-treated HUVECs 
can easily be seen.  Most importantly, CXCL12-α treated HUVECs show a significantly 
greater sprouting ratio response than CXCL12-γ treated HUVECs (P<0.05). These 
findings suggest that the CXCL12-α isoform has a more potent pro-angiogenic effect on 
HUVECs than the CXCL12-γ isoform when in the presence of a collagen-only matrix. 
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Experiments were repeated with hyaluronic acid (1 mg/mL) added to the collagen matrix. 
Representative day 3 images for the collagen/HA sprouting experiments are shown in 
Figure 3.3.   
 
Figure 3.3: Day 3 Images of HUVECs Sprouting into Collagen/HA Matrix 
 HUVECs treated with CXCL12 (α, β, or γ, 100 ng/ml) show a reversed γ>β>α trend in sprouting area 
response with the addition of HA to the matrix. HUVEC behavior shows a shift toward pushing against the 
matrix instead of forming distinct sprouts. PDMS is outline in purple. Scale bars 100 µm. 
Upon initial inspection, two observations can be made. First, the area of HUVECs that 
have moved into the collagen/HA layer reveals an inverted γ>β>α trend compared to 
sprouting into a collagen-only matrix. Obviously, this no longer follows the rank order 
binding affinity of CXCL12 isoforms to CXCR4. This does, however, follow the charge-
based binding affinity of CXCL12 isoforms to the ECM (γ>β>α)[10]. The CXCL12-α treated 
HUVECs show a much-diminished sprouting area response, but the CXCL12-γ treated 
HUVECs seem to be more responsive and now tend to exhibit a fanning out behavior 
similar to what was seen with CXCL12-α treated HUVECs in collagen-only experiments. 
A second observation is that instead of cells forming sprouts, the HUVEC monolayer 
mostly just pushes into the collagen/HA matrix, namely the local expansion of 
microvessels. This interesting behavior is worthwhile for further investigation but one 
possible explanation may be related to how HA affects the stiffness of the matrix. 
 







Sprouting ratio was determined for devices with a collagen/HA matrix in the same way as 
before. Average sprouting ratio for collagen/HA devices are reported in Figure 3.4 (N=3 
devices). 
 
Figure 3.4: Sprouting Ratio of HUVECs into Collagen/HA Matrix over 3-Day Period 
 CXCL12-γ treated HUVECs in a HA-rich matrix show a significant sprouting response increase compared 
to CXCL12-α and β.  Error bars expressed as SEM. Statistical analysis performed using one-way analysis 
of variance. N=3. *, P value < 0.05. 
As seen in the graph, the sprouting ratio trend in CXCL12-treated HUVECS now follows 
a γ>β>α order in a collagen/HA matrix.  Interestingly, CXCL12-γ treated HUVECs show 
a significantly greater sprouting ratio than both CXCL12-α and β treated HUVECs 
(P<0.05). This difference suggests that CXCL12-γ gains a more potent effect on HUVEC 
behavior within a matrix including HA, at least in comparison to CXCL12-α treated 
HUVECs. One further note is that average sprouting ratio decreased in all cases involving 
HA except for in CXCL12-γ treated HUVECs. This is likely associated with how the 
HUVEC monolayers often tended to push into the collagen/HA matrix rather than form 
clear sprouts into the matrix. 
 18 
 
3.2 Quantifying apparent vascular permeability 
Apparent vascular permeability was calculated using Equation 2.2 by observing how 
quickly dye could permeate across the endothelial layer. Average apparent vascular 
permeability values in CXCL12-treated HUVECs were compared between those lining a 
collagen-only matrix and those lining a collagen/HA matrix. Those results are shown in 
Figure 3.5 (N=3-4 devices). 
 
Figure 3.5: Apparent Vascular Permeability Measurements across Endothelial Layer 
In collagen-only experiments, HUVECs cultured with CXCL12 (α, β, or γ, 100 ng/ml) were leakiest when 
treated with CXCL12-α. Addition of HA significantly lowered permeability of control and CXCL12-α treated 
HUVECs but increased CXCL12-γ treated HUVECs to nearly match CXCL12-α. Error bars express SEM. 
Statistical analysis performed using one-way analysis of variance. N=3-4. *, P value < 0.05. 
In collagen-only samples, CXCL12-α treated HUVECs developed much more permeable 
monolayers than untreated HUVECs. CXCL12-β and γ treated HUVECs showed no 
significant difference from control.  With HA added to the matrix, permeability of control 
and CXCL12-α treated HUVECs roughly halved in magnitude while that of CXCL12-γ 
treated HUVECs more than doubled (P<0.05). A decrease in untreated HUVEC 
permeability against a collagen/HA matrix suggests that HA encourages tighter junctions 
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between endothelial cells in those monolayers. This could explain why a significant 
decrease in CXCL12-α treated HUVEC permeability was observed as well.  The increase 
observed in CXCL12-γ treated HUVEC permeability suggests that more isoforms 
remained bound to the matrix outside the endothelium. HA likely enhanced CXCL12-γ’s 
affinity for the matrix, allowing it to more potently disrupt the vessel monolayer. A 
summary of trends seen in the sprouting and permeability results is shown in Table 3.1. 
Table 3.1: Summary of Sprouting and Permeability Results 
In collagen experiments, HUVEC sprouting response followed an α>β>γ trend and CXCL12-α showed the 
greatest impact on vessel permeability. Adding HA reversed the sprouting response trend, weakened the 
CXCL12-α mediated response on permeability, and strengthened CXCL12-γ’s impact on permeability. 
 Sprouting Permeability 
Collagen α>β>γ trend α greatest 







4 Discussion and Conclusions 
4.1 HA stabilizes vessels, lowers vascular permeability 
HA’s role in bodily tissue has been well-documented, but much is still unknown about how 
the presence of HA impacts blood microvessel function and remodeling.  HMW HA has 
been shown to play a role in supporting vessel integrity through receptors on endothelial 
cell membranes such as CD44[17],[18]. That role is complex, however, because it has also 
been shown that as HMW HA gets degraded, the fragmented LMW HA actually disrupts 
the endothelial layer.  Overexpressed HA in the tumor microenvironment is hypothesized 
to increase solid stress in the tissue, and increased solid stress is correlated with leakier 
vessels.  
 
This study’s results support that HA presence in the extracellular matrix helps maintain 
more stable vessels. HMW HA was used in this study, making these results unsurprising, 
but this also implies that no additional solid stress was experienced by the matrix with the 
addition of HA. A possible explanation is that the cells were seeded against a matrix in 
which HA was already present.  The matrix was already fully swelled, and since it was 
not trying to expand after the cells were added, no additional tensile stress was applied 
to the cells that might loosen cell junctions. As a result, the vessel-supporting behavior of 
HMW HA may have been the main factor at play in this system.   
 
4.2 HA enhances matrix affinity, reverses relative CXCL12 isoform potency  
The goal of this study was to determine whether HA’s biochemical properties could affect 
chemokine binding to the ECM and the response potency of endothelial cells. For both 
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sprouting and permeability assays, the presence of HA in the matrix shifted CXCL12 
isoform potency toward a γ>β>α trend, which is unusual given the reverse trend for 
binding affinity to the endothelial cell receptor CXCR4. Given HA’s inherent negative 
charge, it is reasonable that a stronger matrix binding affinity would be observed in the 
more positively-charged CXCL12-γ isoforms than in CXCL12-α isoforms.  The increased 
sprouting and permeability response seen in CXCL12-γ treated HUVECs could be 
explained by the increased concentration of CXCL12-γ remaining bound to the matrix.  
 
4.3 Concluding Remarks 
A few important conclusions can come out of these studies. Hyaluronic acid in this system 
helped stabilize vessels and prevent vessel leakage, supporting previous research that 
HMW HA benefits vessel integrity. Further studies will investigate whether inhibiting HA’s 
receptor CD44 on HUVECs will return vascular permeability to collagen-only control 
levels. Results reveal that HA is capable of shifting relative CXCL12 isoform potency due 
to its dense negative charge. Increased prevalence of matrix-bound CXCL12-γ in 
collagen/HA matrices likely contributes to the increased sprouting and permeability 
response in treated HUVECs. Future studies will perform surface plasmon resonance 
(SPR) techniques on collagen and collagen/HA gels to quantify how much of each specific 
isoform binds to each matrix. Understanding how different ECM compositions affect 
CXCL12 signaling can help in the potential novel development of CXCL12-CXCR4 
pathway-targeting cancer therapies. Overall, this research reveals how HA’s biochemical 
properties could potentially alter chemokine signaling and vessel behavior in the tumor 




[1] Judah Folkman. Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 
1182–1186 (1971). 
[2] Domenico Ribatti. Judah Folkman, a pioneer in the study of angiogenesis. 
Angiogenesis 11, 3-10 (2008).  
[3] Christopher M. Hartshorn, et al. Cancer Nanotechnology Plan 2015. National 
Cancer Institute (2015). 
[4] Sandy Azzi, et al. Vascular Permeability and Drug Delivery in Cancers. Frontiers 
in Oncology 3, 211 (2013). 
[5] Naveen S. Vasudev and Andrew R. Reynolds. Anti-angiogenic therapy for cancer: 
current progress, unresolved questions and future directions. Angiogenesis 17, 
471-494 (2014). 
[6] Sybille Esser, et al. Vascular endothelial growth factor induces VE-cadherin 
tyrosine phosphorylation in endothelial cells. Journal of Cell Science 111, 1853-
1865 (1998). 
[7] Fabian Spill, et al. Impact of the physical microenvironment on tumor progression 
and metastasis. Current Opinion in Biotechnology 40, 41-48 (2016). 
[8] Jacob L. Albritton and Jordan S. Miller. 3D bioprinting: improving in vitro models of 
metastasis with heterogeneous tumor microenvironments. The Company of 
Biologists: Disease Models & Mechanisms 10, 3-14 (2017). 
[9] Nilay Sethi and Yibin Kang. Unravelling the complexity of metastasis — molecular 




[10] Paramita Ray, et al. CXCL12-γ in Primary Tumors Drives Breast Cancer 
Metastasis. Oncogene 34, 2043-2051 (2014). 
[11] Theerawut Chanmee, Pawared Ontong, and Naoki Itano. Hyaluronan: A modulator 
of the tumor microenvironment. Cancer Letters 375, 20-30 (2016). 
[12] Frances E. Lennon and Patrick A. Singleton. Hyaluronan regulation of vascular 
integrity. Am J Cardiovasc Dis 1, 200-213 (2011). 
[13] Raija H. Tammi, et al. Hyaluronan in human tumors: Pathobiological and 
prognostic messages from cell-associated and stromal hyaluronan. Seminars in 
Cancer Biology 18, 288-295 (2008). 
[14] Chrysovalantis Voutouri, et al. Hyaluronan-Derived Swelling of Solid Tumors, the 
Contribution of Collagen and Cancer Cells, and Implications for Cancer Therapy. 
Neoplasia 18, 732-741 (2016). 
[15] Vikash P. Chauhan, et al. Angiotensin inhibition enhances drug delivery and 
potentiates chemotherapy by decompressing tumour blood vessels. Nature 
Communications 4, Article 2516, 1-11 (2013). 
[16] Clifford J. Whatcott, et al. Targeting the Tumor Microenvironment in Cancer: Why 
Hyaluronidase Deserves a Second Look. Cancer Discovery 1 (2011). 
[17] Patrick A. Singleton, et al. High-molecular-weight hyaluronan is a novel inhibitor of 
pulmonary vascular leakiness. Am J Physiol Lung Cell Mol Physiol 299, 639-651 
(2010). 
[18] Norihiro Sato, et al. Role of hyaluronan in pancreatic cancer biology and therapy: 
Once again in the spotlight. Cancer Science 107, 569-575 (2016). 
 24 
 
[19] Caitlin O. McAtee, Joseph J. Barycki, and Melanie A. Simpson. Emerging roles for 
hyaluronidase in cancer metastasis and therapy. Adv Cancer Res 123, 1-34 
(2014). 
[20] Jonathan W. Song, Despina Bazou, and Lance L. Munn, in Vascular 
Morphogenesis (Springer New York), 243-254 (2015). 
[21] Yoojin Shin, et al. Microfluidic assay for simultaneous culture of multiple cell types 
on surfaces or within hydrogels. Nature Protocols 7, 1247-1259 (2012). 
[22] Sarah Y. Yuan and Robert R. Rigor. Regulation of Endothelial Barrier Function. 
Morgan & Claypool Life Sciences (2010).  
